Kotsopoulos J, et al. - Researchers performed a comparison of the hematologic adverse effect profiles associated with platinum-based chemotherapy in ovarian cancer patients with and without germline BRCA mutations. In this study, BRCA mutation carriers showed no frequent hematologic toxicity than the noncarriers among women with ovarian cancer. With respect to dosing regimens, this is reassuring for clinicians treating ovarian cancer patients. Findings thereby did not support the hypothesis that in this high-risk population, a haploinsufficiency phenotype existed with respect to the repair of chemotherapy-induced double-strand DNA breaks.